AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-18 and is reviewed periodically as new material appears.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
== Early life and education == Schmitt was born in Bridgeton, Missouri, a suburb of St. Louis. He graduated from DeSmet Jesuit High School in 1993 and from Truman State University in 1997, with a BA in political science. At Truman, Schmitt was a member of the Alpha Kappa Lambda fraternity, played football and baseball, and was a founding member of Truman's Habitat for Humanity chapter. He received a scholarship to attend Saint Louis University School of Law, where he earned his JD in 2000.
=== Chemical industry === Stainless-steel belts are part of continuous production processes. Unlike conveyor belts used purely for transportation purposes, steel belts used in this industry serve as media for transferring heat and/or pressure. Applications for steel belts in the chemical industry include casting, polymerizing of resins, waxes, paraffins and many other substances.
The IDF said that one in five rockets launched by Hezbollah had landed in Lebanese territory and published an infographic showing failed rocket launches into Israel. On 16 December, a soldier from the IDF's 129th Battalion was killed by a Hezbollah drone strike near Margaliot, which also caused a fire in a building. Two other soldiers were injured. Another drone was shot down by the IDF, which also responded to the infiltrations by shelling targets. The IAF later hit several Hezbollah targets inside Lebanon, including rocket launch sites and military infrastructure. On 22 December, two IDF soldiers of the 188th Armored Brigade were killed by a Hezbollah rocket attack in the Shtula area. On the morning of 23 December, IDF aircraft bombed a house in Kfar Kila and intense artillery fire also took place on the outskirts of Deir Mimas The IDF conducted a raid near a UNIFL center along the Khardali River. An Al-Manar cameraman was injured in the eye after an IDF attack on a road in the al-Khardali area where correspondents of MTV and the state-owned National News Agency were also passing. Hezbollah announced that two of their members were killed on that day. On 24 December, senior IRGC general Razi Mousavi was killed by an Israeli airstrike in Damascus. On 26 December, a Hezbollah anti-tank missile hit St. Mary's Greek Orthodox Church in Iqrit, northern Israel. A civilian suffered serious injuries, and when IDF responders arrived at the scene, another missile was fired, injuring nine soldiers.
Sources: en.wikipedia.org
The acidity of lactic acid impedes biological processes. This can be beneficial to the fermenting organism as it drives out competitors that are unadapted to the acidity. As a result, the food will have a longer shelf life (one reason foods are purposely fermented in the first place); however, beyond a certain point, the acidity starts affecting the organism that produces it. The high concentration of lactic acid (the final product of fermentation) drives the equilibrium backwards (Le Chatelier's principle), decreasing the rate at which fermentation can occur and slowing down growth. Ethanol, into which lactic acid can be easily converted, is volatile and will readily escape, allowing the reaction to proceed easily. CO2 is also produced, but it is only weakly acidic and even more volatile than ethanol. Acetic acid (another conversion product) is acidic and not as volatile as ethanol; however, in the presence of limited oxygen, its creation from lactic acid releases additional energy. It is a lighter molecule than lactic acid, forming fewer hydrogen bonds with its surroundings (due to having fewer groups that can form such bonds), thus is more volatile and will also allow the reaction to proceed more quickly. If propionic acid, butyric acid, and longer monocarboxylic acids are produced, the amount of acidity produced per glucose consumed will decrease, as with ethanol, allowing faster growth.
On 2 August 2015, The FA Community Shield in England was broadcast in Ultra HD by broadcast company BT Sport, becoming the first live football game shown in Ultra HD on the world's first commercial Ultra HD channel. The match was shown on Europe's first Ultra HD channel, BT Sport Ultra HD where selected live English Premier League and European Champions League matches were broadcast. Fashion One 4K launched on 2 September 2015 becoming the first global Ultra HD TV channel. Reaching nearly 370 million households across the world, the fashion, lifestyle and entertainment network broadcasts via satellite from Measat at 91.5°E (for Asia Pacific, Middle East, Australia) and from SES satellites Astra 19.2°E (for Europe), SES-3 at 103°W (for North America), NSS-806 at 47.5°W (for South America). In September 2015, Eutelsat presented new consumer research, conducted by TNS and GfK, on Ultra HD and screen sales in key TV markets. The study looked at consumer exposure to Ultra HD, perceived benefits and willingness to invest in equipment and content. GfK predicts a 200% increase in Ultra HD screen sales from June to December 2015, with sales expected to reach five million by the end of the year. GfK also forecasts that Ultra HD screens in 2020 will represent more than 70% of total sales across Europe and almost 60% in the Middle East and North Africa. On 2 September 2015, Sony unveiled the Xperia Z5 Premium; the first smartphone with a 4K display. On 9 September 2015, Apple Inc. announced that their new smartphone the iPhone 6S could record video in 4K.
Multi/minicore myopathy is a congenital myopathy usually caused by mutations in either the SELENON and RYR1 genes. It is characterised the presence of multifocal, well-circumscribed areas with reduction of oxidative staining and low myofibrillar ATPase on muscle biopsy. It is also known as Minicore myopathy, Multicore myopathy, Multiminicore myopathy, Minicore myopathy with external ophthalmoplegia, Multicore myopathy with external ophthalmoplegia and Multiminicore disease with external ophthalmoplegia.
== Epidemiology == The prevalence of primary polycythemia (polycythemia vera) was estimated to be approximately 44–57 per 100,000 individuals in the United States. Secondary polycythemia is considered to be more common, but its exact prevalence is unknown. In one study using the NHANES dataset, the prevalence of unexplained erythrocytosis is 35.1 per 100,000, and was higher among males and among individuals between ages 50–59 and 60–69.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.